Health care partner Tom Bulleit (Washington, D.C.) was quoted in an Inside Health Policy article published April 12 that examines the Trump administration’s proposal to prohibit pharmaceutical manufacturer rebates to pharmaceutical benefit managers and the health plans they serve.
The article discusses the PBM industry’s view that rebates are protected as a discount or other reduction in price under the anti-kickback statute, so that the U.S. Department of Health and Human Services lacks the authority to withdraw safe harbor protection for that class of discount.
Mr. Bulleit gives the PBM’s argument a better-than-even chance of succeeding in court if the proposed regulation is finalized in its current form.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.